# GLOW Peptide Dosage in the Research Literature | MedsGLOW > GLOW peptide dosage context from the research literature: published dose ranges for GHK-Cu, BPC-157, and TB-500, reconstitution methods, injection routes, and cycle lengths observed in preclinical models. ## GLOW Peptide Dosage in the Research Literature GLOW peptide dosage context below is drawn from published preclinical and clinical research on the individual constituents — GHK-Cu, BPC-157, and TB-500. No controlled clinical trial has evaluated the combined GLOW blend in humans. Dosing in this literature is described as 'administered to [species] at [dose] via [route]' — not as a recommendation for human use. This page addresses [peptide reconstitution protocols](/dosage#reconstitution), [injection routes](/dosage#routes), and published dosing ranges per constituent. ## Published Dosing Ranges for GLOW Peptide Constituents **GHK-Cu.** Fibroblast culture studies administered GHK-Cu at concentrations from 10^-12 M to 10^-9 M to stimulate collagen synthesis [3]. Topical cosmetic and clinical formulations range from 0.1% to 2% by weight in published trials [2]. Pickart estimated systemic therapeutic effect would require 100–200 mg; this estimate has not been validated in a clinical trial. GHK-Cu plasma half-life is estimated at less than 30 minutes per review data, suggesting rapid clearance following systemic administration. **BPC-157.** Rodent model studies use a wide dose range: 10 µg/kg to 10 mg/kg intraperitoneal or subcutaneous [7, 9]. The organ-protection study administered 20 µg/kg IP [10]. In vitro vascular experiments used 0.1–100 µg/mL [5]. BPC-157 is gastric-stable (derived from gastric juice protein) and active via oral gavage in rodent models. Published pharmacokinetic half-life data in peer-reviewed rodent studies has not been located. **TB-500.** Wound healing rodent models used topical and intraperitoneal administration without specified dose units [13]. Human cardiac trials (NCT05984134, Beijing Northland Biotech) administered recombinant thymosin beta-4 at 0.5–1.0 µg/kg IV. Phase I human pharmacokinetic data exists for full thymosin beta-4; TB-500-specific PK data in humans has not been published in peer-reviewed literature. ## Reconstitution Methods Described in the Literature Research protocols for lyophilized peptide blends use bacteriostatic water as the standard diluent. This is documented for both BPC-157 and TB-500 in published research-context protocols. GHK-Cu formulation notes from the published literature: copper chelation requires water as solvent; activity is optimal near neutral pH (approximately 7); strongly acidic solvents reduce activity [4]. Published formulation literature notes incompatibility of GHK-Cu with high ascorbic acid concentrations due to copper reduction chemistry. Standard research-context reconstitution for lyophilized peptides involves adding bacteriostatic water to the vial, allowing it to run down the glass wall, and avoiding agitation that would cause foaming and peptide degradation. Reconstitution volumes vary by study concentration; no GLOW-specific protocol has been published in peer-reviewed literature. GHK-Cu pH compatibility with BPC-157 and TB-500 when co-reconstituted has not been formally evaluated in peer-reviewed literature. ## Injection Routes in GLOW Peptide Research Protocols Published preclinical protocols for BPC-157 and TB-500 use the following routes: **BPC-157:** intraperitoneal (most common in rodent studies), subcutaneous, and oral gavage. The systematic review confirmed activity across all three routes [9]. Oral route is distinctive — gastric stability is a pharmacologically unusual property. **TB-500:** topical and intraperitoneal in wound healing rodent models [13, 14]. Intravenous administration in the human cardiac trial [NCT05984134]. Subcutaneous is most commonly described in research-context protocols in the practitioner literature, but controlled peer-reviewed data for this route in the context of TB-500 specifically is limited. **GHK-Cu:** predominantly topical in cosmetic and clinical trials [2]. Subcutaneous research-context use is referenced in practitioner literature; controlled subcutaneous dosing data is limited in peer-reviewed literature. Short plasma half-life (<30 min estimate) may limit systemic delivery efficacy compared to topical delivery to target tissue sites. ## Cycle Lengths Observed in GLOW Peptide Research Published studies on constituent peptides use a range of protocol durations. GHK-Cu skin studies assessed endpoints at 4–12 weeks (topical, human, photoaged skin trial ran 12 weeks) [2]. GHK-Cu fibroblast senescence in vitro assessed reversal without a specific time window [17]. BPC-157 rodent models ran from single-administration experiments to multi-week protocols. The systematic review found consistent findings across variable study durations [9]. TB-500 wound re-epithelialization was measured at days 4 and 7 in the Malinda et al. wound model [13]; the hair growth transgenic model measured post-depilation regrowth in a 11–16 day window [15]. No clinical trial has formally evaluated optimal GLOW cycle length. Published rodent work on the individual constituents typically runs 4–8 weeks for tissue-repair endpoints. See [frequently asked questions](/faq) for additional protocol-related questions addressed from the published literature. ## GHK-Cu Research Timelines for Skin and Hair Outcomes In vitro, GHK-Cu studies observe collagen gene upregulation within hours of exposure — consistent with direct transcriptional activation [1]. In cultured fibroblasts, collagen synthesis stimulation was measurable at the first assessment point with concentrations starting at 10^-12 M [3]. Animal skin studies assess endpoints at 4–8 weeks. The human cosmetic clinical study ran a 12-week observation window for measurable skin parameter changes in 71 photoaged subjects [2]. Research-context practitioners typically reference 6–12 week windows for assessable skin outcomes, consistent with the published human trial. There is no validated human timeline for the combined GLOW blend. No GLOW-specific clinical trial has established an expected response window. ## How to Dose GLOW Peptide? Preclinical studies on GHK-Cu administered 1–10 mg/kg in some animal models; cosmetic trials used topical 0.1–2% formulations [2, 3]. BPC-157 studies used 10 µg/kg to 10 mg/kg in rodent models, with 20 µg/kg IP used in the 2025 organ protection study [10]. TB-500 studies varied widely, with 0.5–1.0 µg/kg IV in the human cardiac trial. No validated human dosing protocol for the combined GLOW blend exists in the published literature. This page documents what was administered in published research contexts only. --- Three signals monitored from the peer-reviewed record — not a clinic, not a vendor, not a reading that prescribes.